LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 7 of total 7

Search options

  1. Article ; Online: A comprehensive review of COVID-19 symptoms and treatments in the setting of autoimmune diseases

    Hamidi, Zahra / Jabraeili-Siahroud, Shaghaiegh / Taati-Alamdari, Yalda / Aghbash, Parisa Shiri / Shamekh, Ali / Baghi, Hossein Bannazadeh

    Virol J. 2023 Dec., v. 20, no. 1 p.1-1

    2023  

    Abstract: After the first reporting of the index case of Severe Acute Respiratory Syndrome (SARS)-CoV-2-associated disease at the end of December 2019, the virus spread quickly throughout the world, prompting the WHO on 11 March 2020 to declare the disease a ... ...

    Abstract After the first reporting of the index case of Severe Acute Respiratory Syndrome (SARS)-CoV-2-associated disease at the end of December 2019, the virus spread quickly throughout the world, prompting the WHO on 11 March 2020 to declare the disease a global pandemic. The coronavirus disease 2019 (COVID-19) pandemic, raises concerns for all people, mainly for susceptible population. People with pre-existing diseases, especially individuals with autoimmune disorders, are more at the risk of SARS-CoV-2 infection because of compromised immune system due to frequent use of immunosuppressive drugs and steroids. Patients with autoimmune diseases and their physicians have concerns about these patients’ healthcare, since they are at a higher risk for COVID-19 infection, may show severe complications of COVID-19, and may experience probable flares of their pre-existing disease. Even though there have been several studies discussing the relation between COVID-19 and various types of autoimmune diseases, it cannot be ascertained that all patients with autoimmune diseases experience more severe complications of COVID-19 and have more hospitalization or mortality rate. The situation depends on each patient’s condition, such as the type and the severity of the underlying autoimmune disease and the kind of treatment they receive. In the present review, we have discussed the effects of COVID-19 pandemic on patients with different autoimmune diseases and their relative concerns about their treatments. As a result, we have reviewed further considerations that should be taken into account for these patients during the pandemic or when they are infected with COVID-19.
    Keywords COVID-19 infection ; Severe acute respiratory syndrome coronavirus 2 ; at-risk population ; autoimmune diseases ; health services ; immune system ; immunosuppression ; mortality ; pandemic ; patients ; people ; risk ; viruses
    Language English
    Dates of publication 2023-12
    Size p. 1.
    Publishing place BioMed Central
    Document type Article ; Online
    Note Review
    ZDB-ID 2160640-7
    ISSN 1743-422X
    ISSN 1743-422X
    DOI 10.1186/s12985-023-01967-7
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

  2. Article ; Online: The effects of melissa officinalis on depression and anxiety in type 2 diabetes patients with depression: a randomized double-blinded placebo-controlled clinical trial.

    Safari, Mostafa / Asadi, Akbar / Aryaeian, Naheed / Huseini, Hasan Fallah / Shidfar, Farzad / Jazayeri, Shima / Malek, Mojtaba / Hosseini, Agha Fateme / Hamidi, Zahra

    BMC complementary medicine and therapies

    2023  Volume 23, Issue 1, Page(s) 140

    Abstract: Background: Depression is more common in diabetic patients, with a 1.5-fold increased risk of death.Melissa officinalis (M. officinalis) have anti-diabetic and anti-depression activities. The study aimed to determine the efficacy of M. officinalis ... ...

    Abstract Background: Depression is more common in diabetic patients, with a 1.5-fold increased risk of death.Melissa officinalis (M. officinalis) have anti-diabetic and anti-depression activities. The study aimed to determine the efficacy of M. officinalis extract on depression, anxiety, and sleep quality in patients with type 2 diabetes with depressive symptoms.
    Methods: In this double-blind clinical trial, 60 volunteer patients (age range 20-65 years) with type 2 diabetes mellitus with symptoms of depression were randomized into the intervention (received 700 mg/day hydroalcoholic extract; n = 30) or control group (received 700 mg/day toasted flour; n = 30). Dietary intake, physical activity, anthropometric indices, FBS (Fasting blood sugar), hs-CRP(High-sensitivity C-reactiveprotein), depression, anxiety, and sleep quality were determined at the beginning and end of the study. Depression and anxiety were assessed by Beck Depression Inventory-II (BDI-II) and Beck Anxiety Inventory (BAI), respectively; sleep quality was evaluated using the Pittsburgh Sleep Quality Index (PSQI).
    Results: Sixty participants received M. officinalis extract or placebo, of which 44 patients completed the 12-week double-blind clinical trial. After 12-week the mean change of depression and anxiety scores were statistically significant between the two groups (p < 0.001 and p = 0.04, respectively), but no significant differences were observed in FBS, hs-CRP, anthropometric indices, sleep quality, and blood pressure.In the intervention group, there was a significant decrease in depression and anxiety severity(p < 0.001 and p = 0.01, respectively) at the end of the study compared to the baseline.
    Trial registration: All protocols in this study were followed in accordance with the Helsinki Declaration (1989 revision). Ethical approval for this study was obtained from the Iran University of Medical Sciences Ethics committee (IR.IUMS.FMD.REC 1396.9413468004; research.iums.ac.ir). The study was registered at the Iranian Registry of Clinical Trials (IRCT201709239472N16); Registration date: 09/10/2017.
    MeSH term(s) Humans ; Infant, Newborn ; Infant ; Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/drug therapy ; Melissa ; Iran ; C-Reactive Protein ; Anxiety/drug therapy
    Chemical Substances C-Reactive Protein (9007-41-4)
    Language English
    Publishing date 2023-05-02
    Publishing country England
    Document type Randomized Controlled Trial ; Journal Article
    ISSN 2662-7671
    ISSN (online) 2662-7671
    DOI 10.1186/s12906-023-03978-x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: A comprehensive review of COVID-19 symptoms and treatments in the setting of autoimmune diseases.

    Hamidi, Zahra / Jabraeili-Siahroud, Shaghaiegh / Taati-Alamdari, Yalda / Aghbash, Parisa Shiri / Shamekh, Ali / Baghi, Hossein Bannazadeh

    Virology journal

    2023  Volume 20, Issue 1, Page(s) 1

    Abstract: After the first reporting of the index case of Severe Acute Respiratory Syndrome (SARS)-CoV-2-associated disease at the end of December 2019, the virus spread quickly throughout the world, prompting the WHO on 11 March 2020 to declare the disease a ... ...

    Abstract After the first reporting of the index case of Severe Acute Respiratory Syndrome (SARS)-CoV-2-associated disease at the end of December 2019, the virus spread quickly throughout the world, prompting the WHO on 11 March 2020 to declare the disease a global pandemic. The coronavirus disease 2019 (COVID-19) pandemic, raises concerns for all people, mainly for susceptible population. People with pre-existing diseases, especially individuals with autoimmune disorders, are more at the risk of SARS-CoV-2 infection because of compromised immune system due to frequent use of immunosuppressive drugs and steroids. Patients with autoimmune diseases and their physicians have concerns about these patients' healthcare, since they are at a higher risk for COVID-19 infection, may show severe complications of COVID-19, and may experience probable flares of their pre-existing disease. Even though there have been several studies discussing the relation between COVID-19 and various types of autoimmune diseases, it cannot be ascertained that all patients with autoimmune diseases experience more severe complications of COVID-19 and have more hospitalization or mortality rate. The situation depends on each patient's condition, such as the type and the severity of the underlying autoimmune disease and the kind of treatment they receive. In the present review, we have discussed the effects of COVID-19 pandemic on patients with different autoimmune diseases and their relative concerns about their treatments. As a result, we have reviewed further considerations that should be taken into account for these patients during the pandemic or when they are infected with COVID-19.
    MeSH term(s) Humans ; COVID-19/complications ; SARS-CoV-2 ; Pandemics ; Autoimmune Diseases/complications
    Language English
    Publishing date 2023-01-07
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2160640-7
    ISSN 1743-422X ; 1743-422X
    ISSN (online) 1743-422X
    ISSN 1743-422X
    DOI 10.1186/s12985-023-01967-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: The effect of saffron supplement on clinical outcomes and metabolic profiles in patients with active rheumatoid arthritis: A randomized, double‐blind, placebo‐controlled clinical trial

    Hamidi, Zahra / Aryaeian, Naheed / Abolghasemi, Jamileh / Shirani, Fatemeh / Hadidi, Mahsa / Fallah, Soudabeh / Moradi, Nariman

    Phytotherapy research. 2020 July, v. 34, no. 7

    2020  

    Abstract: Rheumatoid arthritis (RA) is a systemic autoimmune and inflammatory disease. Our study aimed to determine the effect of saffron supplement on clinical outcomes and metabolic profiles in patients with active RA. In this randomized, double‐blind, placebo‐ ... ...

    Abstract Rheumatoid arthritis (RA) is a systemic autoimmune and inflammatory disease. Our study aimed to determine the effect of saffron supplement on clinical outcomes and metabolic profiles in patients with active RA. In this randomized, double‐blind, placebo‐controlled trial, 66 women older than 18 years old received 100 mg/day either saffron supplement in the intervention group (n = 33) or matched placebo in the placebo group (n = 33) for a period of 12 weeks. Sixty‐one patients (30 in the control and 31 in the saffron group) remained for the final analysis. No adverse effects were reported by the patients. Saffron supplementation significantly decreased the number of tender (−1.38 ± 1.66 vs. 0.10 ± 0.40, p < .001) and swollen (−2.12 ± 2.34 vs. 0.63 ± 2.79, p < .001) joints, pain intensity based on visual analogue scale (−18.36 ± 15.07 vs. −2.33 ± 5.04), p < .001), and disease activity score (DAS28) (−0.75 ± 0.67 vs. 0.26 ± 0.77, p < .001) at the end of intervention between the two groups and in saffron group compared with baseline values. Physician Global Assessment (p = .002) and erythrocyte sedimentation rate were significantly improved after intervention (24.06 ± 12.66 vs. 32.00 ± 14.75, p = 0.028). High‐sensitivity C‐reactive protein reduced at the end of the intervention in the saffron group compared with baseline values (12.00 ± 7.40 vs. 8.82 ± 7.930, p = .004). Tumor necrosis factor alpha, interferon gamma, and malondialdehyde were decreased, and total antioxidant capacity were increased, but their differences between the two groups were not significant (p > .05). According to the results, saffron supplements could positively and significantly improve clinical outcomes in RA patients.
    Keywords C-reactive protein ; adverse effects ; antioxidant activity ; clinical trials ; erythrocyte sedimentation rate ; interferon-gamma ; malondialdehyde ; normal values ; pain ; patients ; phytotherapy ; placebos ; research ; rheumatoid arthritis ; saffron ; tumor necrosis factor-alpha ; women
    Language English
    Dates of publication 2020-07
    Size p. 1650-1658.
    Publishing place John Wiley & Sons, Ltd.
    Document type Article
    Note NAL-light ; JOURNAL ARTICLE
    ZDB-ID 639136-9
    ISSN 1099-1573 ; 0951-418X
    ISSN (online) 1099-1573
    ISSN 0951-418X
    DOI 10.1002/ptr.6633
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

  5. Article ; Online: The effect of saffron supplement on clinical outcomes and metabolic profiles in patients with active rheumatoid arthritis: A randomized, double-blind, placebo-controlled clinical trial.

    Hamidi, Zahra / Aryaeian, Naheed / Abolghasemi, Jamileh / Shirani, Fatemeh / Hadidi, Mahsa / Fallah, Soudabeh / Moradi, Nariman

    Phytotherapy research : PTR

    2020  Volume 34, Issue 7, Page(s) 1650–1658

    Abstract: Rheumatoid arthritis (RA) is a systemic autoimmune and inflammatory disease. Our study aimed to determine the effect of saffron supplement on clinical outcomes and metabolic profiles in patients with active RA. In this randomized, double-blind, placebo- ... ...

    Abstract Rheumatoid arthritis (RA) is a systemic autoimmune and inflammatory disease. Our study aimed to determine the effect of saffron supplement on clinical outcomes and metabolic profiles in patients with active RA. In this randomized, double-blind, placebo-controlled trial, 66 women older than 18 years old received 100 mg/day either saffron supplement in the intervention group (n = 33) or matched placebo in the placebo group (n = 33) for a period of 12 weeks. Sixty-one patients (30 in the control and 31 in the saffron group) remained for the final analysis. No adverse effects were reported by the patients. Saffron supplementation significantly decreased the number of tender (-1.38 ± 1.66 vs. 0.10 ± 0.40, p < .001) and swollen (-2.12 ± 2.34 vs. 0.63 ± 2.79, p < .001) joints, pain intensity based on visual analogue scale (-18.36 ± 15.07 vs. -2.33 ± 5.04), p < .001), and disease activity score (DAS28) (-0.75 ± 0.67 vs. 0.26 ± 0.77, p < .001) at the end of intervention between the two groups and in saffron group compared with baseline values. Physician Global Assessment (p = .002) and erythrocyte sedimentation rate were significantly improved after intervention (24.06 ± 12.66 vs. 32.00 ± 14.75, p = 0.028). High-sensitivity C-reactive protein reduced at the end of the intervention in the saffron group compared with baseline values (12.00 ± 7.40 vs. 8.82 ± 7.930, p = .004). Tumor necrosis factor alpha, interferon gamma, and malondialdehyde were decreased, and total antioxidant capacity were increased, but their differences between the two groups were not significant (p > .05). According to the results, saffron supplements could positively and significantly improve clinical outcomes in RA patients.
    MeSH term(s) Arthritis, Rheumatoid/drug therapy ; Crocus/chemistry ; Double-Blind Method ; Female ; Humans ; Male ; Middle Aged ; Treatment Outcome
    Language English
    Publishing date 2020-02-11
    Publishing country England
    Document type Journal Article ; Randomized Controlled Trial
    ZDB-ID 639136-9
    ISSN 1099-1573 ; 0951-418X
    ISSN (online) 1099-1573
    ISSN 0951-418X
    DOI 10.1002/ptr.6633
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: PIK3R1 Mutation Associated with Hyper IgM (APDS2 Syndrome): A Case Report and Review of the Literature.

    Yazdani, Reza / Hamidi, Zahra / Babaha, Fateme / Azizi, Gholamreza / Fekrvand, Saba / Abolhassani, Hassan / Aghamohammadi, Asghar

    Endocrine, metabolic & immune disorders drug targets

    2019  Volume 19, Issue 7, Page(s) 941–958

    Abstract: Background and objective: APDS [Activated phosphoinositide 3-kinase (PI3K) δ Syndrome] is a newly found special form of primary immunodeficiency caused by mutations in genes encoding PI3Kδ subunits and over-activation of the PI3K signaling pathway. Gain- ...

    Abstract Background and objective: APDS [Activated phosphoinositide 3-kinase (PI3K) δ Syndrome] is a newly found special form of primary immunodeficiency caused by mutations in genes encoding PI3Kδ subunits and over-activation of the PI3K signaling pathway. Gain-of-function and loss-of-function mutations in PIK3CD (encoding P110δ) and PIK3R1 (encoding p85α, p55α and p50α) lead to APDS1 and APDS2, respectively. The subsequent irregular PI3K downstream signaling cascade is associated with abnormalities in B cells and T cells and the consequent heterogeneous clinical manifestations including respiratory tract infections, autoimmunity, lymphoproliferation and not to mention primary antibody deficiency. In this study, we report a 12-year-old girl with a mutation in the PIK3R1 gene who manifested immunological phenotypes resembling hyper IgM syndrome along with a review of the literature of the previously reported patients.
    Methods: Whole exome sequencing was performed to detect the underlying genetic mutation in this patient.
    Results: A de novo heterozygous splice site mutation in the hot spot of the PIK3R1 gene within the intron 10 was found (c.1425+1G>A).
    Conclusion: Further investigations are required for evaluation of the underlying genetic defects and the possible associations between genetic underpinning and heterogeneous severity and features of the disease.
    MeSH term(s) Child ; Class I Phosphatidylinositol 3-Kinases/genetics ; Class Ia Phosphatidylinositol 3-Kinase/genetics ; Fatal Outcome ; Female ; Humans ; Hyper-IgM Immunodeficiency Syndrome/diagnosis ; Hyper-IgM Immunodeficiency Syndrome/genetics ; Mutation/genetics ; Primary Immunodeficiency Diseases/diagnosis ; Primary Immunodeficiency Diseases/genetics
    Chemical Substances PIK3R1 protein, human (EC 2.7.1.-) ; Class I Phosphatidylinositol 3-Kinases (EC 2.7.1.137) ; Class Ia Phosphatidylinositol 3-Kinase (EC 2.7.1.137)
    Language English
    Publishing date 2019-02-22
    Publishing country United Arab Emirates
    Document type Case Reports ; Journal Article ; Review
    ZDB-ID 2228325-0
    ISSN 2212-3873 ; 1871-5303
    ISSN (online) 2212-3873
    ISSN 1871-5303
    DOI 10.2174/1871530319666190225114739
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Book ; Thesis: Zur Phonologie des Persischen

    Hamidi, Zahra

    System und Geschichte

    2006  

    Author's details von Zahra Hamidi
    Keywords Persisch ; Phonologie
    Language German
    Size XIV, 266 S., graph. Darst.
    Document type Book ; Thesis
    Thesis / German Habilitation thesis Univ., Diss.--München, 2003
    Database Library catalogue of the German National Library of Science and Technology (TIB), Hannover

    More links

    Kategorien

To top